United States Patent 9,308,204: Scope, Claim Architecture, and US Patent Landscape
What does US Patent 9,308,204 claim cover?
US 9,308,204 claims two drug-product compositions built around a single defined small-molecule entity, combined with either sitagliptin or metformin, plus a generic pharmaceutically acceptable excipient.
Core chemical entity (present in all independent claims)
All compositions recite:
- (1S,2S,3S,4R,5S)-5-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-1-hydroxymethyl-6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol
This is the invention anchor. Everything else is formulation language or an added active.
Independent claims and combination partners
Claim 1 (composition + sitagliptin)
- The defined bicyclic triol compound + pharmaceutically acceptable excipient + sitagliptin
Claim 2 (composition + metformin)
- The same defined bicyclic triol compound + pharmaceutically acceptable excipient + metformin
Dependent claims: therapeutically effective amount
Claim 3
- Claim 1 composition where the bicyclic triol is present in a therapeutically effective amount
Claim 4
- Claim 2 composition where the bicyclic triol is present in a therapeutically effective amount
How broad is the claim scope in the US?
The patent scope is constrained by two structural elements and then broadened by generic formulation language.
1) Hard constraint: exact chemical identity
The bicyclic triol is recited with a full stereochemical and structural descriptor. Any product that changes:
- stereochemistry,
- substitution pattern, or
- the bicyclo[3.2.1]octane-2,3,4-triol scaffold,
does not fall within the literal claim language. The wording is “comprising,” so additional actives are not excluded, but the claimed compound must be present.
2) Hard constraint: exact combination partner (in independent claims)
Claim 1 requires sitagliptin. Claim 2 requires metformin. A product that uses a different DPP-4 inhibitor (other than sitagliptin) or a different antidiabetic (other than metformin) would not meet the literal requirement of those independent claims.
3) Soft constraint: excipient language is generic
“Pharmaceutically acceptable excipient, diluent, or carrier” is classic breadth. It covers essentially all standard formulation approaches (tablet, capsule, immediate-release, controlled release, etc.) unless the specification imposes narrower limitations. The claim text you provided does not specify dosage form.
4) “Therapeutically effective amount” expands practical coverage
Claims 3 and 4 add only the conventional amount limitation. They do not define a numerical range, dosing regimen, or ratio between actives, so coverage is not numerically restricted based solely on the claim text provided.
What is the likely legal “infringement map” for this patent?
Based on the claim set provided, infringement analysis in the US will usually proceed in layers.
Layer A: Does the product contain the exact bicyclic triol with the stated stereochemistry?
This is the gating element for all claims (1-4). If the active is absent, there is no literal infringement.
Layer B: Is sitagliptin or metformin also present?
- If sitagliptin is present, evaluate Claim 1 / Claim 3
- If metformin is present, evaluate Claim 2 / Claim 4
Mixed inclusion (both sitagliptin and metformin) can still satisfy “comprising,” but the independent claims still require one of those named actives as part of the composition.
Layer C: Is there a pharmaceutically acceptable excipient/carrier?
This will almost always be met for regulated drug products.
Layer D: Does the bicyclic triol appear in a therapeutically effective amount?
For product labeling and PK/PD-based dosing, this usually becomes a factual question. The claims do not fix ranges, so the effective-amount argument is typically driven by dosage instructions and clinical pharmacology.
Claim construction: what the words do (and do not do)
“A pharmaceutical composition comprising”
This is open-ended. It does not exclude additional components, including:
- additional excipients,
- additional actives (unless separately limited by dependent claim structure or specification context).
“Pharmaceutically acceptable excipient, diluent, or carrier”
This is a broad category that typically covers typical tablet/capsule formulations, including binders, disintegrants, lubricants, coatings, and possibly sustained-release matrices.
“Therapeutically effective amount”
This is functional and not numerically limited in the provided claim text. It typically does not require any specific mechanism, patient subgroup, or endpoint in the claim language you provided.
Is there any procedural or strategic signal in claim structure?
Yes: the patent appears to stake coverage on a combo-therapy composition anchored to one defined chemical entity and two well-known antidiabetic actives.
- It covers both a DPP-4 inhibitor (sitagliptin) and metformin, which together map to common type 2 diabetes treatment paradigms.
- It uses composition claims, not method-of-treatment claims in the text you provided. That means enforcement is often product-based, not regimen-based.
US patent landscape: how this claim set typically positions against US filings
Without the full prosecution history, family members, and the specification, a complete “citations map” cannot be reconstructed from the claim text alone. What can be stated from the claim set is the likely landscape segmentation:
1) Potential “overlap” zones: fixed-dose combinations and adjunct active formulations
US practice frequently sees:
- combination product filings that claim the same or similar actives,
- later improvements that add a second known antidiabetic agent,
- reformulations that add or swap excipient systems.
This patent’s combination partners are two major reference drugs. That tends to create overlap opportunities for later entrants who seek to combine metformin with other agents, or who market DPP-4 inhibitor combinations.
2) Potential “non-overlap” zones: other DPP-4 inhibitors or other biguanides
Any competitor who uses:
- a DPP-4 inhibitor other than sitagliptin, or
- a biguanide other than metformin,
should avoid the named partner elements of Claims 1 and 2 unless the claim language in the full patent broadens partner identity elsewhere (not shown in the text provided).
3) Potential “design-around” zone: changing stereochemistry or molecular identity
Because the bicyclic triol is specified with full stereochemistry, competitors can attempt to avoid literal infringement by using:
- a different stereoisomer,
- a close analog that does not match the recited structural definition.
Whether such analogs would still infringe under doctrine of equivalents depends on claim construction and prosecution history not provided here.
Practical scope scenarios (literal-claim screening)
Scenario 1: Fixed-dose or co-pack product containing the exact triol + sitagliptin
- Likely within Claim 1 and Claim 3 if the triol amount is therapeutically effective.
Scenario 2: Formulation containing the exact triol + metformin
- Likely within Claim 2 and Claim 4 if the triol amount is therapeutically effective.
Scenario 3: Triol formulation alone (no sitagliptin, no metformin)
- Not covered by Claims 1 or 2 as written.
Scenario 4: Triol + another DPP-4 inhibitor (not sitagliptin)
- Not covered by Claim 1 as written.
Scenario 5: Triol + another biguanide (not metformin)
- Not covered by Claim 2 as written.
What does the patent likely do in a portfolio sense?
On a portfolio basis, this patent functions as a combination-use commercial barrier tied to a specific molecular entity. It does not appear, based on the claims provided, to:
- protect the triol alone,
- protect methods of treatment,
- protect broader antidiabetic partner classes.
So the enforceable “surface area” is tied to product formulations that include both:
- the exact triol entity with the stated stereochemistry, and
- one named antidiabetic co-active (sitagliptin or metformin).
Key claim coverage matrix (from the text provided)
| Claim |
Required bicyclic triol |
Required co-active |
Excipients/carrier |
Therapeutically effective amount |
| 1 |
Yes |
Sitagliptin |
Yes (generic) |
Not explicitly required in claim 1 text |
| 2 |
Yes |
Metformin |
Yes (generic) |
Not explicitly required in claim 2 text |
| 3 |
Yes |
Sitagliptin |
Yes (generic) |
Yes, for triol |
| 4 |
Yes |
Metformin |
Yes (generic) |
Yes, for triol |
Key Takeaways
- US 9,308,204 is a composition patent with two independent claims built around the same precisely defined stereochemical bicyclic triol.
- Coverage is divided by named co-actives: sitagliptin (Claims 1 and 3) or metformin (Claims 2 and 4).
- The excipient language is broad (“pharmaceutically acceptable excipient, diluent, or carrier”), making the product form less of a limiting factor than the active ingredient match.
- The most direct design-around strategies are to avoid at least one required element: the exact triol identity, or the named co-active (sitagliptin/metformin).
FAQs
-
Does this patent cover the bicyclic triol by itself?
No. Based on Claims 1-4 as provided, coverage requires the triol plus either sitagliptin or metformin.
-
Can a product with additional active ingredients still infringe?
Likely yes, because the claims use “comprising,” which is open-ended, so long as the triol and the named co-active are present.
-
Is the dosage form restricted (tablet vs capsule vs solution)?
The claim language provided does not restrict dosage form; it only requires a pharmaceutically acceptable excipient/carrier.
-
Are sitagliptin and metformin interchangeable under the claims?
No. Claim 1 requires sitagliptin; Claim 2 requires metformin.
-
Do Claims 3 and 4 add numerical dosing limits?
No. They add only a functional “therapeutically effective amount” limitation for the bicyclic triol.
References
[1] United States Patent 9,308,204. Claims as provided in the prompt (Claims 1-4).
